TD Cowen Upgrades Spero Therapeutics (SPRO) to Buy
TD Cowen analyst Ritu Baral upgraded Spero Therapeutics (NASDAQ: SPRO) from Hold to Buy.
The analyst comments "2Q24: We are upgrading SPRO to Buy on new clarity on catalyst timing and optimism for '720 Ph2a data in the 2nd half of 4Q24. The monotx trial in fl-NTM (enrollment now complete) looks at change in early bacterial load in sputum samples from BL to end of tx (at D56d) analyzed as a slope vs. PBO. Topline data from 2 Ph1 HV '720 trials also due in 4Q24. $63.5M cash gives runway into late '25."
For an analyst ratings summary and ratings history on Spero Therapeutics click here. For more ratings news on Spero Therapeutics click here.
Shares of Spero Therapeutics closed at $1.34 yesterday.